Patents by Inventor Louis M. Pelus
Louis M. Pelus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230279353Abstract: The receptor EP4 is identified as the PGE2 receptor that is most responsible enhancing the homing and engraftment of hematopoietic stem and progenitor cells. Treatment of graft sources and graft recipients with compounds that preferentially target the EP4 receptor provide effective methods of increasing engraftment success while minimizing adverse side effects that may Obe associated with therapies that include the use of less selective molecules such as PGE2 and dmPGE2. One effective molecule used in such therapies is 5-[(1E,3R)-4,4-ditluoro-3-hydroxy-4-phenyl-1-buten-1-yl]-1-[6-(2H-tetrazol-5R-yl)hexyl]-2-pyrrolidinone or a pharmaceutically acceptable salt thereof (L-902, 685).Type: ApplicationFiled: October 3, 2022Publication date: September 7, 2023Inventors: Louis M. Pelus, Jonathan Hoggatt
-
Publication number: 20220313735Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non?steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.Type: ApplicationFiled: December 14, 2021Publication date: October 6, 2022Inventors: Louis M. Pelus, Jonathan Hoggatt, Pratibha Singh
-
Patent number: 11459545Abstract: The receptor EP4 is identified as the PGE2 receptor that is most responsible enhancing the homing and engraftment of hematopoietic stem and progenitor cells. Treatment of graft sources and graft recipients with compounds that preferentially target the EP4 receptor provide effective methods of increasing engraftment success while minimizing adverse side effects that may be associated with therapies that include the use of less selective molecules such as PGE2 and dmPGE2. One effective molecule used in such therapies is 5-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-buten-1-yl]-1-[6-(2H-tetrazol-5R-yl)hexyl]-2-pyrrolidinone or a pharmaceutically acceptable salt thereof (L-902, 688).Type: GrantFiled: November 15, 2010Date of Patent: October 4, 2022Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: Louis M. Pelus, Jonathan Hoggatt
-
Patent number: 11241454Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.Type: GrantFiled: May 11, 2017Date of Patent: February 8, 2022Assignee: Indiana University Research & Technology CorporationInventors: Louis M. Pelus, Jonathan Hoggatt, Pratibha Singh
-
Patent number: 10213460Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.Type: GrantFiled: June 27, 2014Date of Patent: February 26, 2019Assignee: Indiana University Research and Technology Corp.Inventors: Louis M. Pelus, Jonathan Hoggatt, Pratibha Singh
-
Publication number: 20170304362Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.Type: ApplicationFiled: May 11, 2017Publication date: October 26, 2017Inventors: Louis M. Pelus, Jonathan Hoggatt, Pratibha Singh
-
Patent number: 9675641Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.Type: GrantFiled: March 4, 2015Date of Patent: June 13, 2017Assignee: Indiana University Research & Technology CorporationInventors: Louis M. Pelus, Jonathan Hoggatt, Pratibha Singh
-
Publication number: 20160030478Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.Type: ApplicationFiled: March 4, 2015Publication date: February 4, 2016Inventors: Louis M. Pelus, Jonathan Hoggatt, Pratibha Singh
-
Patent number: 9107909Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.Type: GrantFiled: November 6, 2009Date of Patent: August 18, 2015Assignee: Indiana University Research & Technology Corp.Inventors: Louis M. Pelus, Jonathan Hoggatt, Pratibha Singh
-
Publication number: 20140377214Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-infiammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.Type: ApplicationFiled: June 27, 2014Publication date: December 25, 2014Inventors: Louis M. Pelus, Jonathan Hoggatt, Pratibha Singh
-
Publication number: 20140065706Abstract: Disclosed herein are materials and methods such as the use of none steroidal anti-inflammatory drugs to increase the number of CD34+ cell in human patients. The level of ECFC measured in volunteers before and after treatment with meloxicam. Only 4/7 volunteers had detectable levels of ECFC in a 40 mL sample of peripheral of blood (PB) before treatment, while 7/7 had detectable levels of ECFC in a similar sample collected post-meloxicam treatment. Administering a course of treatment with NSAID also increased the number of endothelial colony forming cells (ECFC) in the volunteers PB and it reduced culture time to first ECFC detection. These data demonstrate that NSAID administration mobilizes both hematopoietic and endothelial progenitors to PB. This provides a safe and effective strategy that can be added to existing mobilization regimens and is especially useful when combined with a course of treatment that includes the use of G-CSF.Type: ApplicationFiled: November 7, 2011Publication date: March 6, 2014Applicant: Indiana University Research and Technology Corp.Inventors: Louis M. Pelus, Jonathan Hoggatt
-
Publication number: 20140017339Abstract: Disclosed herein are materials and methods for treating patients that have been exposed to pathological levels on ionizing radiation. These materials and methods include administering to a patient in thereof at least one dose of a compound such as prostaglandin (PGE2) as soon as possible after the patient has been exposed to the radiation. Additional embodiments include treating a patient exposed to radiation with at least one dose of a compound that modulates PGE2 activity such as non-steroidal anti-inflammatory compound. Some methods include a first step of administering PGE2 or another compound that binds as soon as possible after exposure to radiation followed by a delayed dosing with at least one compound such as meloxicam that interferes with PGE2 activity.Type: ApplicationFiled: November 7, 2011Publication date: January 16, 2014Applicant: Indiana University Research and Technology Corp.Inventors: Louis M. Pelus, Jonathan Hoggatt
-
Publication number: 20120003189Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.Type: ApplicationFiled: November 6, 2009Publication date: January 5, 2012Inventors: Louis M. Pelus, Jonathan Hoggatt, Pratibha Singh
-
Publication number: 20100178271Abstract: Methods to mobilize progenitor and/or stem cells from the bone marrow to the bloodstream by administering a combination of at least one CXCR4 inhibitor, at least one CXCR2 agonist, and G-CSF are described. The combinations may also be used to increase the effectiveness of chemotherapy and radiation therapies for hematopoietic malignancies.Type: ApplicationFiled: August 7, 2007Publication date: July 15, 2010Applicant: GENZYME CORPORATIONInventors: Gary J. Bridger, Louis M. Pelus
-
Publication number: 20100003224Abstract: Methods to mobilize progenitor and/or stem cells from the bone marrow to the bloodstream by administering a combination of at least one CXCR4 inhibitor and at least one VLA-4 inhibitor are described. The combinations may also be used to treat multiple myeloma.Type: ApplicationFiled: August 2, 2007Publication date: January 7, 2010Applicant: GENZYME CORPORATIONInventors: Gary J. Bridger, Louis M. Pelus
-
Publication number: 20020155094Abstract: The invention relates to the method of preventing and treating sepsis and ARDS using chemokine or biologically active fragment thereof, alone or in conjunction with an anti-infective agent.Type: ApplicationFiled: March 25, 2002Publication date: October 24, 2002Applicant: Smithkline Beecham CorporationInventors: John R. White, Louis M. Pelus